Executive Summary: State-of-the-Art Review: Hepatitis C

Vincent Lo Re 3rd¹, Debika Bhattacharya², Jennifer Price³, Andrew Aronsohn⁴, H Nina Kim⁵, Seun Falade-Nwulia⁶, Matty Zimmerman¹, Stacey Trooskin⁷, Jessie Torgersen¹

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
² Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
³ Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
⁴ Department of Infectious Disease, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA.
⁵ Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
⁶ Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
⁷ Executive Medical Officer, Mazzoni Center, Philadelphia, Pennsylvania, USA.

PMID: 40971898
DOI: 10.1093/cid/ciaf335

Executive Summary: State-of-the-Art Review: Hepatitis C

Vincent Lo Re 3rd et al. Clin Infect Dis. 2025.

. 2025 Sep 16;81(2):217-219.

doi: 10.1093/cid/ciaf335.

Authors

Vincent Lo Re 3rd¹, Debika Bhattacharya², Jennifer Price³, Andrew Aronsohn⁴, H Nina Kim⁵, Seun Falade-Nwulia⁶, Matty Zimmerman¹, Stacey Trooskin⁷, Jessie Torgersen¹

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
² Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
³ Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
⁴ Department of Infectious Disease, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA.
⁵ Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
⁶ Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
⁷ Executive Medical Officer, Mazzoni Center, Philadelphia, Pennsylvania, USA.

PMID: 40971898
DOI: 10.1093/cid/ciaf335

No abstract available

Keywords: HCV elimination; HCV infection; cascade of care; direct-acting antiviral therapy; hepatitis C virus.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest . V. L. R. received grant funding from GlaxoSmithKline. D. B. received grant funding from Gilead. J. C. P. received grant funding from AbbVie, Genentech, and Gilead. O. F. N. received grant funding from AbbVie and Advisory fees from Gilead. S. T. received Advisory fees from Gilead. The remaining authors have no conflicts to report.

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Executive Summary: State-of-the-Art Review: Hepatitis C

Affiliations

Executive Summary: State-of-the-Art Review: Hepatitis C

Authors

Affiliations

Conflict of interest statement

LinkOut - more resources

Full Text Sources